The role of human aldo-keto reductases in the metabolic activation and detoxication of polycyclic aromatic hydrocarbons: interconversion of PAH catechols and PAH o-quinones

Li Zhang, Yi Jin, Meng Huang and Trevor M. Penning*

Center of Excellence in Environmental Toxicology, Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Polycyclic aromatic hydrocarbons (PAH) are ubiquitous environmental pollutants. They are procarcinogens requiring metabolic activation to elicit their deleterious effects. Aldo-keto reductases (AKRs) catalyze the oxidation of proximate carcinogenic PAH trans-dihydriodols to yield electrophilic and redox-active PAH o-quinones. AKRs are also found to be capable of reducing PAH o-quinones to form PAH catechols. The interconversion of o-quinones and catechols results in the redox-cycling of PAH o-quinones to give rise to the generation of reactive oxygen species and subsequent oxidative DNA damage. On the other hand, PAH catechols can be intercepted through phase II metabolism by which PAH o-quinones could be detoxified and eliminated. The aim of the present review is to summarize the role of human AKRs in the metabolic activation/detoxication of PAH and the relevance of phase II conjugation reactions to human lung carcinogenesis.

Keywords: polycyclic aromatic hydrocarbons, o-quinones, aldo-keto reductases, conjugation reactions, phase II metabolism, redox-cycling

INTRODUCTION

The Aldo-keto reductases (AKRs) are a superfamily of monomeric NAD(P)(H)-dependent oxidoreductases. They are cytosolic and have ~320 amino acids with molecular weights around 34–37 kDa (Jez et al., 1997). AKRs catalyze the reduction of aldehydes and ketones to yield primary and secondary alcohols on a variety of endogenous substrates and xenobiotics (Hara et al., 1996; Jin and Penning, 2007), and are formal phase I metabolic enzymes. AKRs have been implicated in a number of human diseases. AKR1B1 (aldose reductase) is implicated in the complications that arise due to diabetes, since it converts high blood glucose to the hyperosmotic sugar sorbitol (Lee et al., 1995; Suzen and Buyukbingol, 2003). AKR1B10 (retinal reductase) is involved in retinoic acid signaling and is implicated in the pathogenesis of lung cancer (Fukumoto et al., 2005; Penning and Lerman, 2008) and hepatocellular carcinoma (Liu et al., 2012). By contrast, AKR1C family members play essential roles in metabolism of male and female sex hormones and may play roles in the development of hormone dependent malignancies of the prostate and breast (Penning and Byrns, 2009); while AKR1D1 (steroid 5β-reductase) is essential for bile-acid biosynthesis and inherited mutations in the AKR1D1 gene are associated with bile-acid deficiency (Lemonde et al., 2003). The present review will focus on roles of AKRs in metabolism of polycyclic aromatic hydrocarbons (PAH).

Polycyclic aromatic hydrocarbons are ubiquitous environmental pollutants. They are suspect lung carcinogens and are products of tobacco smoke and incomplete fossil fuel combustion (Grimmer and Bohnke, 1975; Burczynski et al., 1999). PAH are characterized by the presence of two or more fused non-hetero aromatic rings arranged in various configurations (Fetzer, 2007). Based on the arrangement of their aromatic rings, PAH can be categorized into non-bay-region (e.g., naphthalene), bay-region (e.g., benzo[a]pyrene), and fjord-region (e.g., benzo[g]chrysene) PAH (Figure 1). Based on the number of the aromatic rings, the common PAH can be divided into the naphthalene (two rings), phenanthrene (three rings), chrysene, and 5-methyl-chrysene (four rings), benzo[a]pyrene (B[a]P), and benzo[g]chrysene (five rings) series, etc. Benzo[a]pyrene is a representative PAH and widely used to study the mutagenic and carcinogenic effects of PAH (Conney, 1982; Cavaliere and Kogan, 1993). PAH are not reactive and require metabolic activation to form electrophiles to elicit their deleterious effects, thus they are procarcinogens (Gelboin, 1980). There are three major pathways for the activation of B[a]P, which result in the formation of radical cations, diol epoxides, and electrophilic and redox-active o-quinones (Figure 2). In the present review, we will focus on the o-quinone pathway and discuss the role of human AKRs in the formation of the o-quinones, the redox-cycling of o-quinones to form catechols, and the removal of catechols by conjugating enzymes. For details about the other pathways, readers are referred to previous review papers (Penning et al., 1999; Penning, 2004; Xue and Warshawsky, 2005).

ACTIVATION OF PAH trans-DIHYDRODIOLS BY AKRs TO FORM o-QUINONES

In the o-quinone pathway of PAH activation, the proximate PAH carcinogens, trans-dihydriodols, e.g., B[a]P-7,8-trans-dihydriodiol, are oxidized by AKRs to yield ketols which spontaneously rearrange to form catechols, e.g., B[a]P-7,8-catechol...
The curly arrow denotes the presence of a bay-region; a methylated bay-region or a fjord-region.

(Figure 2; Burczynski et al., 1998; Palackal et al., 2001, 2002). B[a]P-7,8-catechol is not stable and undergoes autoxidation to yield B[a]P-7,8-dione. PAH α-quinones are electrophilic and highly reactive to endogenous nucleophiles. PAH α-quinones can readily form conjugates with cellular thiols to yield α-cysteine, N-acetyl-α-cysteine (NAC), and GSH conjugates leading to their elimination (Murty and Penning, 1992a,b). PAH α-quinones can also react with DNA to form both stable and depurinating adducts in vitro which may result in mutagenesis (Shou et al., 1993; McCoull et al., 1999; Balu et al., 2006). PAH α-quinones are also able to undergo non-enzymatic/enzymatic reduction to reform catechols at the expense of NADPH and establish futile redox cycles which amplify the generation of reactive oxygen species (ROS). ROS can cause DNA damage resulting in the formation of 7,8-dihydro-8-oxo-2′-deoxyguanosine (8-oxo-dGuo) lesions, contributing to G-to-T transversions in K-ras and p53 (Kasai et al., 1986; Cheng et al., 1992). PAH α-quinones were found to be more mutagenic than diol epoxides in an in vitro p53 mutagenesis assay and a linear correlation was observed between the mutagenic efficiency and the presence of 8-oxo-dGuo in the p53 cDNA (Yu et al., 2002; Park et al., 2006; Shen et al., 2006). More recently, the metabolic activation of B[a]P-7,8-trans-dihydrodiol to B[a]P-7,8-dione was demonstrated in human lung adenocarcinoma (A549) cells which shows high constitutive expression of AKRs. This metabolic activation led to the formation ROS and 8-oxo-dGuo lesions in cellular DNA (Park et al., 2008).

Several members of the AKR superfamily are able to oxidize PAH trans-dihydrodiols to α-quinones (Smithgall et al., 1986, 1988). The substrate specificity of AKRs covers structurally diverse PAH trans-dihydrodiols which range from the simplest trans-1,2-dihydroxy-1,2-dihydro-naphthalene, to bay-region dihydrodiols (e.g., trans-1,2-dihydroxy-1,2-dihydrochrysene), to methylated bay-region dihydrodiols (e.g., trans-3,4-dihydroxy-3,4-dihydro-7-methylbenz[a]anthracene), and to fjord-region dihydrodiols (e.g., trans-11,12-dihydroxy-11,12-dihydrobenzo[g]chrysene). In contrast, K-region dihydrodiols, in which the dihydroxy groups are located on a central benzo-ring, (e.g., trans-9,10-dihydroxy-9,10-dihydrobenz[a]anthracene) and trans-4,5-dihydroxy-4,5-dihydroB[a]P) are not substrates of AKRs (Table 1; Palackal et al., 2001, 2002; Shultz et al., 2008).

In considering the human enzymes, AKR1A1 was stereoselective and will only oxidize (−)-B[a]P-7(R),8(R)-dihydrodiol, which is the major stereoisomer formed in vivo. Similarly, AKR1A1 oxidized (−)-benz[a]anthracene-3(R),4(R)-dihydrodiol, (+)-7-methylbenz[a]anthracene-3(S),4(S)-dihydrodiol, and (−)-7,12-dimethylbenz[a]anthracene-3(R),4(R)-dihydrodiol rather than both diastereomers (Table 1; Palackal et al., 2001).
AKR1B10 is one of the most overexpressed genes in non-small lung carcinoma and a member of the smoking gene battery that is up-regulated in response to cigarette smoking and down-regulated in smokers who quit (Fukumoto et al., 2005; Zhang et al., 2008). AKR1B10 was found to oxidize a wide range of PAH trans-dihydrodiol substrates in vitro to yield PAH o-quinones, but showed improper stereospecificity with B[a]P-7,8-dihydrodiol in that it only oxidized the minor (+)-B[a]P-7(S),8(S)-dihydrodiol isomer. The related subfamily member AKR1B1 displayed the same stereochemical specificity as AKR1B10 on racemic B[a]P-7,8-trans-dihydrodiols (Quinn et al., 2008). The stereochemical preference of AKR1B10 appears to be limited only to B[a]P-7,8-trans-dihydrodiol and benzo[a]anthracene-3,4-diol, since no stereospecificity for the oxidation of the (−)-R,R and (+)-S,S stereoisomers of benzo[g]chrysene-11,12-dihydrodiol and 7,12-dimethylbenz[a]anthracene-3,4-diol was noted.

Four human AKR1C subfamily members (AKR1C1-AKR1C4) oxidized B[a]P-7,8-trans-dihydrodiol to B[a]P-7,8-dione in the following rank order: AKR1C2 > AKR1C1 > AKR1C3 > AKR1C4 (Burczynski et al., 1998). AKR1C1-AKR1C4 oxidized both stereoisomers of racemic trans-dihydrodiols, although AKR1C1 and AKR1C2 displayed a preference for the (+)-B[a]P-7(S),8(S)-dihydrodiol isomer (Burczynski et al., 1998). AKR1C1-AKR1C4 showed high activity for both stereoisomers of the bay-region substituted PAH trans-dihydriodiois, where bay-region substituted PAH are more carcinogenic than B[a]P (Table 1; Palackal et al., 2002).

**REDUCTION OF PAH o-QUINONES BY AKRs**

The metabolic activation of B[a]P-7,8-trans-dihydriodioi to B[a]P-7,8-dione was demonstrated in human lung adenocarcinoma A549 cells which show high constitutive expression of AKRs (Park et al., 2008). This metabolic activation led to the formation of ROS and 8-oxo-dGuo lesions in cellular DNA. Importantly, oxidative stress was exacerbated in the presence of a catechol-O-methyl transferase (COMT) inhibitor (Park et al., 2008). This observation indicated that the redox-cycling between B[a]P-7,8-dione and B[a]P-7,8-catechol occurred with a concomitant generation of ROS which in turn resulted in DNA damage. COMT was able to intercept the catechol and thus protect against the insult from redox-cycling. When B[a]P-7,8-dione was given to human bronchoalveolar H358 cells, similar exacerbation of cellular oxidative DNA damage was observed in the presence of a COMT inhibitor (Mangal et al., 2009). Both COMT cell-based studies clearly suggest that two electron reduction of the PAH o-quinone to the PAH catechol not only results in oxidative stress and DNA damage, but also leads to O-methylation and detoxication of PAH o-quinones at the level of PAH catechols (Figure 2).

The enzymatic two electron reduction of quinones to hydroquinones is thought to be able to protect against quinone-induced
cellular oxidative stress, because the hydroquinone would be available for phase II conjugation reactions. However, if the rates of conjugation reactions are overwhelmed by the rate of the ensuing redox-cycling, the reduction process may be deleterious (Figure 2). It is not well understood which enzymes account for the process of two electron reduction of PAH-quinones to PAH catechols and contribute to redox-cycling. Candidate enzymes that may catalyze the two electron reduction of PAH-quinones are the redox-cycling enzymes, which are products of PAH-quinones. The ability of homogenous recombinant NQO1, CBRs, and AKRs to reduce PAH-quinones were compared (Shultz et al., 2011). Except for discrete o-quinones, the rank order of activity was: NQO1 > AKR7A2 > CBRs.

NQO1 is a flavoenzyme that catalyzes the electron reduction of quinones to hydroquinones by using NAD(P)H as an electron donor (Jaiswal et al., 1988). Despite its high o-quinone reductase activity, NQO1 did not appear to be the dominant enzyme that catalyzes o-quinone reduction in human lung A549 cells since treatment with NQO1 inhibitor, dicumarol did not eliminate the deleterious ROS generated by PAH o-quinone redox-cycling (Shultz et al., 2011) suggesting that CBR would not play a critical role in the two electron reduction of PAH o-quinones.

AKR1C9 (rat liver 3α-hydroxyoxygenoid/dihydrodiol dehydrogenase) was first found to catalyze the reduction of B[a]P-7,8-dione at an unexpectedly staggering rate of 4750 nmol/min/mg which was three orders of magnitude greater than the rate of conversion of B[a]P-7,8-trans-dihydrodiol to B[a]P-7,8-dione catalyzed by the same enzyme (Smithgall et al., 1986; Flowers-Geary et al., 1992). In further studies, a panel of purified human AKRs (AKR 1A1, 1B1, 1B10, 1C1-1C4, 7A2, and 7A3) were shown to catalyze the reduction of B[a]P-7,8-dione and other PAH o-quinones with the specific activities that were 100–1000 times greater than their respective activities to oxidize the cognate PAH trans-dihydrodiol.

Table 1 | Oxidation of PAH trans-dihydrodiols by human AKRs.

| PAH trans-dihydrodiols | ARK1A1 | ARK1B1 | ARK1B10 | ARK1C1 | ARK1C2 | ARK1C3 | ARK1C4 | AKR7A2 | AKR7A3 |
|------------------------|--------|--------|---------|--------|--------|--------|--------|--------|--------|
| Naphthalene-1,2-diol    | 10.4a  | NA     | NA      | 151b   | 100b   | 6.4b   | 32.7b  | NA     | NA     |
| NON-K-REGION DIHYDRODIOLS |      |        |         |        |        |        |        |        |        |
| Phenanthrene-1,2-diol   | 17.9a  | NA     | NA      | NDb    | NA     | NA     | NA     | NA     | NA     |
| Chrysene-1,2-diol       | 15.5a  | NA     | NA      | NDb    | 7.0b   | 4.26b  | 10b    | NA     | NA     |
| Benzo[a]anthracene-3,4-diol | (-) 68.1a | NA   | (+) 12.8b | 9.5b  | 17.6b  | 18.0b  | 32.2b  | NA     | NA     |
| Benzo[k]pyrene-7,8-diol | (-) 29.8b | (+) 10.3a | (+) 2.36b | 22.6b | 53.3b  | 24.7b  | 16.7b  | NDc    | NDc    |
| METHYLATED DERIVATIVES |      |        |         |        |        |        |        |        |        |
| 7-Methylbenzo[a]anthracene-3,4-diol | (+) 85.8b | NA   | NA      | 4.8b   | 49.5b  | 30.1b  | 46.9b  | NA     | NA     |
| 7,12-Dimethylbenzo[a]anthracene-3,4-diol | (-) 97.1a | NA   | 2.7a   | 7.4b   | 46.8b  | 19.7b  | 185b   | NA     | NA     |
| 7-Methylchrysene-7,8-diol | 130a  | NA     | NA      | 12.4b  | 28.8b  | 9.0b   | 35.2b  | NA     | NA     |
| K-REGION DIHYDRODIOLS  |      |        |         |        |        |        |        |        |        |
| Phenanthrene-9,10-diol  | NDb   | NA     | NA      | NDb    | NA     | NA     | NA     | NA     | NA     |
| Benzo[k]pyrene-4,5-diol | NDb   | NA     | NA      | NDb    | NA     | NA     | NA     | NA     | NA     |
| BJORD-REGION DIHYDRODIOLS |      |        |         |        |        |        |        |        |        |
| Benzo[c]phenanthrene-3,4-diol | 11.8a  | NA     | 1.5a   | NDb    | 4.3b   | 6.6b   | 8.2b   | NA     | NA     |
| Benzo[g]chrysene-11,12-diol | 11.3a  | NA     | 9.55a  | 4.5b   | 4.9b   | 23b    | 165b   | NA     | NA     |

*Palackal et al., 2001,* *Shultz et al., 2011,* *Quinn et al., 2008:* ND: not detected; + or – in parenthesis, stereospecificity of AKR to the PAH trans-dihydrodiols where no parenthesis exist the AKR isomorph oxidizes both isomers of the racemic mixture.
Table 2 | Reduction of B[a]P-7,8-dione by human AKRs.

| AKR       | B[a]P-7,8-dione reduction (nmol/min/mg) |
|-----------|----------------------------------------|
| AKR1A1    | 350                                    |
| AKR1B1    | 250                                    |
| AKR1B10   | 250                                    |
| AKR1C1    | 64                                     |
| AKR1C2    | 350                                    |
| AKR1C3    | 130                                    |
| AKR1C4    | 130                                    |
| AKR1D1    | ND                                     |
| AKR7A2    | 1270                                   |
| AKR7A3    | 1170                                   |

Data from: Shultz et al., 2011.

o-quinones catalyzed by AKRs was demonstrated to lead to futile redox cycles. In each instance, 10 μM PAH o-quinone consumed 180 μM NADPH, and the consumption of cofactor was accompanied by a concomitant consumption of molecular oxygen and the production of superoxide anion and hydrogen peroxide (Shultz et al., 2011).

The contribution of individual AKRs to the redox-cycling, if PAH o-quinones are in lung, will depend on their levels of expression and catalytic efficiency for each PAH o-quinone substrate. Although AKR1A1 catalyzes the most effective oxidation of the major enantiomer of B[a]P-trans-dihydrodiol in vivo, (−)-B[a]P-7(8R)-dihydrodiol (Palackal et al., 2001), it has the lowest quinone reductase activity among all AKRs for most PAH o-quinones (Shultz et al., 2011). Also, the expression level of AKR1A1 in normal human bronchoalveolar cells is very low (Jiang et al., 2006; Quinn and Penning, 2008), which implies that AKR1A1 is not critical in the enzymatic reduction of PAH o-quinones in the lung.

AKR1B10 has a wide substrate specificity for PAH o-quinones and exhibits high catalytic efficiency for each PAH o-quinone substrate. Although AKR1A1 catalyzes the most effective oxidation of the major enantiomer of B[a]P-trans-dihydrodiol in vivo, (−)-B[a]P-7(8R),8(7R)-dihydrodiol (Palackal et al., 2001), it has the lowest quinone reductase activity among all AKRs for most PAH o-quinones (Shultz et al., 2011). Also, the expression level of AKR1A1 in normal human bronchoalveolar cells is very low (Jiang et al., 2006; Quinn and Penning, 2008), which implies that AKR1A1 is not critical in the enzymatic reduction of PAH o-quinones in the lung.

The contribution of individual AKRs to the redox-cycling, if PAH o-quinones are in lung, will depend on their levels of expression and catalytic efficiency for each PAH o-quinone substrate. Although AKR1A1 catalyzes the most effective oxidation of the major enantiomer of B[a]P-trans-dihydrodiol in vivo, (−)-B[a]P-7(8R),8(7R)-dihydrodiol (Palackal et al., 2001), it has the lowest quinone reductase activity among all AKRs for most PAH o-quinones (Shultz et al., 2011). Also, the expression level of AKR1A1 in normal human bronchoalveolar cells is very low (Jiang et al., 2006; Quinn and Penning, 2008), which implies that AKR1A1 is not critical in the enzymatic reduction of PAH o-quinones in the lung.

AKR1B10 has a wide substrate specificity for PAH o-quinones and exhibits high catalytic efficiency for each PAH o-quinone substrate. Although AKR1A1 catalyzes the most effective oxidation of the major enantiomer of B[a]P-trans-dihydrodiol in vivo, (−)-B[a]P-7(8R),8(7R)-dihydrodiol (Palackal et al., 2001), it has the lowest quinone reductase activity among all AKRs for most PAH o-quinones (Shultz et al., 2011). Also, the expression level of AKR1A1 in normal human bronchoalveolar cells is very low (Jiang et al., 2006; Quinn and Penning, 2008), which implies that AKR1A1 is not critical in the enzymatic reduction of PAH o-quinones in the lung.

AKR1B10 has a wide substrate specificity for PAH o-quinones and exhibits high catalytic efficiency for each PAH o-quinone substrate. Although AKR1A1 catalyzes the most effective oxidation of the major enantiomer of B[a]P-trans-dihydrodiol in vivo, (−)-B[a]P-7(8R),8(7R)-dihydrodiol (Palackal et al., 2001), it has the lowest quinone reductase activity among all AKRs for most PAH o-quinones (Shultz et al., 2011). Also, the expression level of AKR1A1 in normal human bronchoalveolar cells is very low (Jiang et al., 2006; Quinn and Penning, 2008), which implies that AKR1A1 is not critical in the enzymatic reduction of PAH o-quinones in the lung.

AKR1B10 has a wide substrate specificity for PAH o-quinones and exhibits high catalytic efficiency for each PAH o-quinone substrate. Although AKR1A1 catalyzes the most effective oxidation of the major enantiomer of B[a]P-trans-dihydrodiol in vivo, (−)-B[a]P-7(8R),8(7R)-dihydrodiol (Palackal et al., 2001), it has the lowest quinone reductase activity among all AKRs for most PAH o-quinones (Shultz et al., 2011). Also, the expression level of AKR1A1 in normal human bronchoalveolar cells is very low (Jiang et al., 2006; Quinn and Penning, 2008), which implies that AKR1A1 is not critical in the enzymatic reduction of PAH o-quinones in the lung.

The contribution of individual AKRs to the redox-cycling, if PAH o-quinones are in lung, will depend on their levels of expression and catalytic efficiency for each PAH o-quinone substrate. Although AKR1A1 catalyzes the most effective oxidation of the major enantiomer of B[a]P-trans-dihydrodiol in vivo, (−)-B[a]P-7(8R),8(7R)-dihydrodiol (Palackal et al., 2001), it has the lowest quinone reductase activity among all AKRs for most PAH o-quinones (Shultz et al., 2011). Also, the expression level of AKR1A1 in normal human bronchoalveolar cells is very low (Jiang et al., 2006; Quinn and Penning, 2008), which implies that AKR1A1 is not critical in the enzymatic reduction of PAH o-quinones in the lung.

Although the expression of AKR7A2 is low in A549 cells, its superior catalytic efficiency for most of PAH o-quinones as well as its capability of reducing dimethylbenz[a]anthracene-3,4-dione and benz[a]anthracene-3,4-dione which are non-substrates of other AKRs may make it play a role in the reduction of these PAH o-quinones in lung (Quinn et al., 2008; Shultz et al., 2011).

DETOXICATION OF PAH o-QUINONES BY HUMAN COMT

The observation that ROS generation from PAH o-quinone in A549 cells was exacerbated by a COMT inhibitor infers that metabolable PAH catechols are formed in lung cells and that these catechols can be intercepted by COMT (Park et al., 2008). COMT is a classical phase II enzyme and catalyzes the transfer of a methyl group from S-adenosyl-l-methionine (SAM) to the hydroxyl group of a variety of catechols including catecholamine neurotransmitters and the catechol estrogens (Axelrod and Tomchick, 1958; Axelrod, 1966; Ball et al., 1972). There are two major COMT isoforms in human, the soluble cytosolic form (S-COMT), and the membrane-bound endoplasmic reticulum form (MB-COMT), encoded by a single gene at 22q11.2 (Grossman et al., 1992; Tenhunen et al., 1994). The two isoforms share identical amino acid sequences except that the MB-COMT contains an NH2 terminal extension of 50 amino acids to serve as a hydrophobic anchor to the membrane (Ulmanen and Lundstrom, 1991). COMT is widely distributed among various organs in the body including lung where high COMT activity was found (Mannisto and Kaakkola, 1999). Except in brain, S-COMT is the predominant form in most tissues (Jeffery and Roth, 1984; Grossman et al., 1985; Tenhunen and Ulmanen, 1993).

Polycyclic aromatic hydrocarbons o-quinones are structurally related to the estrogen o-quinones, which demonstrate similar genotoxic modes of action (Penning et al., 1999; Bolton et al., 2000; Bolton and Thatcher, 2008). The formation and detoxication of estrogen o-quinones are well studied and can be used as parallel for the studies of PAH o-quinone detoxication. The biotransformation of estrogens such as 17β-estradiol and estrone is primarily catalyzed via P450 pathways to yield the 2-hydroxy and 4-hydroxyl catechol estrogens (Aoyama et al., 1990; Kerlan et al., 1992; Martucci and Fishman, 1993; Shou et al., 1997). Both catechol estrogens can be further oxidized to an estrogen o-quinone which could form stable and depurinating DNA adducts (Lieber et al., 1986; Stack et al., 1996; Cavaliere et al., 1997). The detoxication of catechol estrogens can occur by O-methylation catalyzed by COMT (Schneider et al., 1984; Dawling et al., 2001).

The detoxication of PAH o-quinones by COMT was investigated recently (Zhang et al., 2011). B[a]P-7,8-dione was reduced to the catechol by dithiothreitol anaerobically in the presence of S-adenosyl-l-methionine and further O-methylated by human recombinant COMT (Zhang et al., 2011; Figure 3). COMT showed quite a wide substrate specificity and O-methylated a series of structurally diverse PAH catechols such as bay-region, methylated bay-region and fjord-region PAH catechols. PAH catechols often formed two isomeric products. For B[a]P-7,8-catechols, the two...
FIGURE 3 | In vitro COMT and SULT assay to measure O-methylation and O-sulfation of PAH o-quinones.

products were formed at a ratio of 9:1 with the major metabolite being O-8-monomethyl-B[a]P-7,8-catechol (Zhang et al., 2011).

Catalytic efficiencies ($k_{cat}/K_m$) of O-methylation of PAH catechols by COMT varied greatly among the classes of PAH catechols studied (Table 3). PAH catechols containing a methylated bay-region or a fjord-region, which have bent structures due to steric clashing of bay-region hydrogen atoms, have high efficiency of O-methylation. However, pronounced substrate inhibition was also observed with these PAH catechols. Since substrate inhibition occurs at low micromolar concentrations, these PAH catechols may not be efficiently detoxified by COMT and thus are more likely to undergo redox-cycling to cause ROS generation (Zhang et al., 2011).

The human COMT gene has a common G to A polymorphism that results in valine to methionine substitution at residue 108 for S-COMT or residue 158 for MB-COMT. Compared with the wild type, the Met/Met homozygous COMT activity in red blood cells was reduced by half, and the Met/Val heterozygous COMT showed intermediate activity for 3,4-dihydroxybenzoic acid (Syvanen et al., 1997). The low activity of the COMT mutant is related to its poor thermostability at physiological temperature, and not due to different kinetic properties. This SNP in the COMT gene has been associated with an increased risk of lung cancer (Zienolddiny et al., 2008; Cote et al., 2009). As COMT can act as a detoxification enzyme for PAH catechols, it is possible that these polymorphic variants may increase susceptibility to lung cancer caused by PAH.

DETOXICATION OF PAH o-QUINONES BY HUMAN SULFOTRANSFERASES AND URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASES

While methylation of estrogen catechols has been found as an important pathway for detoxication of estrogen o-quinones, both sulfate and glucuronide conjugates of estrogen catechols catalyzed by the human sulfotransferases (SULTs) and uridine diphosphate glucuronosyltransferases (UGTs), respectively, has been observed (Brueggemeier et al., 1984; Adjei and Weinshilboum, 2002; Taskinen et al., 2003; Hui et al., 2008). Since PAH o-quinones are structurally related to the estrogen o-quinones, it is very likely that sulfation and glucuronidation of PAH catechols represent other pathways of detoxication of PAH o-quinones. SULTs are a group of cytosolic enzymes responsible for the transfer of a sulfonate group from 3′-phosphoadenosine 5′-phosphosulfate (PAPS) to either a hydroxyl moiety or an amine group (Negishi et al., 2001). SULTs catalyze the sulfate conjugation of steroid hormones, neurotransmitters, drugs, and xenobiotic compounds (Coughtrie et al., 1998). On the basis of amino acid sequence identity, human SULTs are divided into two main families SULT1 and SULT2, which are also termed the phenol sulfotransferase and the hydroxysteroid sulfotransferase family, respectively. SULT enzymes have a broad tissue distribution including liver, lung, brain, skin, etc. (Cappiello et al., 1989).

In a recent study, it was revealed that SULT1A1, 1A3, and 1E1, were expressed in human lung adenocarcinoma A549 cells, human
Table 3 | O-methylation of PAH catechols by COMT.

| Quinone                      | $k_{cat}/K_m$ (min$^{-1}$ μM$^{-1}$) | Substrate inhibition | M1 (%) | M2 (%) |
|------------------------------|------------------------------------|----------------------|--------|--------|
| Naphthalene-1,2-dione        | 4.9                                | –                    | 100    | 0      |
| Chrysene-1,2-dione           | 1.7                                | +                    | 62     | 38     |
| Chrysene-3,4-dione           | 0.02                               | –                    | 83     | 16     |
| 5-Methyl-chrysene-7,8-dione  | 10.1                               | –                    | 55     | 45     |
| Benz(a)anthracene-3,4-dione  | 4.0                                | +                    | 59     | 41     |
| 7-Methylbenz(a)anthracene-3,4-dione | 1.6                             | +                    | 53     | 47     |
| 12-Methylbenz(a)anthracene-3,4-dione | 9.0                             | +                    | 62     | 38     |
| 7,12-Dimethylbenz(a)anthracene-3,4-dione | 6.8                             | +                    | 32     | 68     |
| Benzo[c]phenanthrene-3,4-dione | 3.5                             | –                    | 67     | 34     |
| B[a]P-7,8-dione              | 0.7                                | –                    | 90     | 10     |
| Benzo[g]chrysene-11,12-dione | 8.0                                | +                    | 36     | 64     |
| Pyrocatechol                 | 0.2                                | –                    | NA     | NA     |

a%, Product as isomer 1; b%, Product as isomer 2.
+,- Where substrate inhibition is observed; –, substrate inhibition is not observed.

Data from: Zhang et al., 2011.

bronchoalveolar H358 cells, immortalized human bronchial epithelial cells (HBEC-KT), and normal human bronchial epithelial cells (BEAS-2B; Zhang et al., 2012). When $B[a]P$-7,8-dione was reduced anaerobically to the catechol, it was found to be a substrate for these three human recombinant SULTs, and produced two $O$-sulfated products (Zhang et al., 2012). In these assays, the metastable PAH catechol was generated anaerobically and further sulfated by SULTs using PAPS as the sulfate donor (Figure 3). Two isomeric mono-$O$-sulfated-$B[a]P$-7,8-catechols were generated and their identities were confirmed by LC-MS-MS and 2D$^1$H NMR. The major metabolite formed by SULT1A3 was found to be 8-hydroxy-$B[a]P$-7,8-sulfate with the minor metabolite being 7-hydroxy-$B[a]P$-8-O-sulfate. SULT1A1 only generated the 8-hydroxy-$B[a]P$-7-O-sulfate metabolite. SULT1E1 generated similar amounts of both isomers. SULTs displayed $K_m$ values in the low micromolar or sub-micromolar range which were compatible or even lower than those for estrogen catechols (Zhang et al., 2012). The studies indicate that sulfation of PAH catechols by SULTs could be an important phase II pathway for the detoxification of PAH $o$-quinones, and that the major enzyme involved was SULT1A1.

SULT1A1 polymorphism has been associated with increased lung cancer risk (Wang et al., 2002). The common SULT1A1 alleles consist of *1 (wild type), *2 variant (Arg213His), and *3 variant (Met223Val; Carlini et al., 2001). The allelic frequencies for SULT1A1*1, *2, *3 in Caucasian were 0.656, 0.332, 0.012, respectively. Despite the low frequency of SULT1A1*3 in Caucasians, it has an allelic frequency of 0.229 in African-Americans (Carlini et al., 2001). It has been reported that SULT1A1 recombinant alleles have variable thermal stability and specific activity toward $p$-nitrophenol, catechol estrogens, and dietary flavonoids (Rafiqogianis et al., 1999; Adjei and Weinshilboum, 2002; Nagar et al., 2006). The SULT1A1*2 variant was associated with low enzyme activity and thermal stability (Rafiqogianis et al., 1999; Wang et al., 2002; Nagar et al., 2006). Although SULT1A1*3 had compatible thermal stability of the wild type, its specific activities for SULT1A1 substrates were lower than that of the wild type in many cases (Nagar et al., 2006). Our study showed that the catalytic efficiency of SULT1A1*3 with $B[a]P$-7,8-catechol was about 50% of the wild type SULT1A1. Therefore, polymorphic variants of SULT1A1 may have reduced efficiency to detoxify PAH $o$-quinones. Unlike the high allelic frequencies of SULT1A1 variants, SULT1A3, and SULT1E1 variants were found to be very rare which suggests that genetic polymorphism of these two enzymes may have minimal effect on PAH $o$-quinone detoxication (Glatt and Meinl, 2004; Hildebrandt et al., 2004).

Uridine diphosphateglucuronosyltransferases are superfamily of microsomal enzymes catalyzing the glucuronidation of a variety of endogenous compounds and xenobiotics (King et al., 2000). Based on sequence identities, UGTs are divided into two main subfamilies, UGT1 and UGT2 (Tukey and Strassburg, 2000). UGTs are widely distributed in a variety of tissues, including liver, intestine, brain, kidney, lung, etc. (Guillemette, 2003). Several UGTs were found to catalyze the glucuronidation of PAH mono-phenols and dihydrodiols (Zheng et al., 2001; Olson et al., 2011). The major enzyme isoforms that glucuronidate PAH catechols remain to be identified.

**DETOXIFICATION OF PAH O-QUINONES IN HUMAN LUNG CELLS**

The existence of Phase II detoxication of PAH $o$-quinones was confirmed in human lung cells (A549, H358, and HBEC-KT cells; Huang et al., 2012b). Consistent with the studies that used human recombinant enzymes, both mono-$O$-methylated $B[a]P$-7,8-catechol and mono-$O$-hydroxy-$B[a]P$-7,8-sulfate were formed in three human lung cells. The detection of these metabolites in human lung cells suggests that $O$-methylation and sulfation of PAH catechols are critical pathways in detoxication of PAH $o$-quinones in human lung. Evidence for the formation PAH catechol glucuronides was also found, although absolute chemical structures of them require elucidation.
In addition to the formation of O-methylated, O-sulfate, and O-glucuronide conjugates of B[a]P-7,8-catechol, the glutathione (GSH) conjugate, NAC conjugate, and a B[a]P-7,8-dione adenine adduct were also detected in human lung cells (Figure 4; Huang et al., 2012a,b). PAH o-quinones were reported to readily form thioether conjugates with l-cysteine and GSH conjugates in vitro (Smithgall et al., 1986; Murty and Penning, 1992a,b). Thio-conjugation occurred at C10 of B[a]P-7,8-dione (Murty and Penning, 1992a). The GSH and NAC conjugates of B[a]P-7,8-dione formed in the human lung cells were found to be identical to those obtained from non-enzymatic synthesis (Huang et al., 2012b). However, glutathione S-transferase (GSTs) may also be involved. To form the NAC conjugate of B[a]P-7,8-dione, the GSH conjugate would be converted into a Cys-Gly conjugate by \(\gamma\)-glutamyltranspeptidase, and then further metabolized into a Cys conjugate by the action of a dipeptidase, and ultimately the NAC conjugate would be formed by \(N\)-acetyl transferase (Blair, 2006, 2010). Future studies will be required to identify the GST isoforms involved in the thio-conjugation of PAH o-quinones. Although thio-conjugation of o-quinones could enhance the polarity and solubility of PAH o-quinones to facilitate the disposition of PAH, the ability of these o-quinone thioether conjugates to redox-cycling remains (Monks and Lau, 1997). It was shown that GSH conjugates of benzoquinone undergo redox-cycling to produce renal toxicity. In this respect, thioether conjugates are not completely innocuous. 1,4-Michael addition of PAH o-quinones with DNA could also give rise to depurinating and stable DNA adducts. Treatment of lung cells (A549, H358, and HBEC-KT) with 2 \(\mu\)M B[a]P-7,8-dione

**FIGURE 4 | Metabolic pathways of B[a]P-7,8-dione in human lung cells.** Metabolites of B[a]P-7,8-dione detected from human lung cells are underlined (Huang et al., 2012b). Ade, adenosine.
consistently generated a B[a]P-7,8-dione adduct (Huang et al., 2012a). Sources of this adduct other than DNA exist, since adenine is a key component of NAD(P)(H) and ATP, and the acid conditions used in its isolation could lead to glycosidic and ester bond cleavage. Thus it is not possible to conclude that this adduct came from DNA.

Our data support the concept that AKRs not only activate PAH trans-dihydrodiols by forming redox-active PAH o-quinones, but also facilitate the redox-cycling of the PAH o-quinones to catechols. The catechols are available for conjugation by a wide range of Phase II enzymes (Figure 2). Phase II conjugation of PAH catechols will significantly alter the detrimental properties of PAH o-quinone on lung cells. First, it terminates the futile redox-cycling of PAH o-quinones that leads to ROS generation and subsequent oxidative DNA damage. Second, it eliminates the electrophilicity of PAH o-quinone and prevents the formation of covalent adducts with protein and DNA. Finally, glucuronidation and sulfation usually result in more polar metabolites with enhanced renal or biliary excretion of xenobiotics or drugs, thus conjugation of PAH catechols may also facilitate elimination of PAH o-quinones from the body. Since AKRs are involved in activation and deactivation of PAH, it is important to study the expression of AKRs in human lung cells so as to understand the contribution of each AKR isoform in toxification and detoxication of PAH in lung. Except liver-specific AKR1C4, AKR1C1, 1C2, 1C3 were found to be highly expressed in human lung tissue (Penning et al., 2000) were overexpressed in non-small-cell lung carcinoma (Fukumoto et al., 2005; Woenckhaus et al., 2006), and can be induced by PAH (Burczynski et al., 1999; Courter et al., 2007; Misaki et al., 2007; Machala et al., 2008). Transcript levels of AKR1A1, AKR1C, AKR1B, and AKR7A2 isoforms were compared in A549 cells (Quinn et al., 2008). AKR1B1 and particularly AKR1B10 were the most abundant AKR isoforms followed by AKR1C isoforms, while the expression of AKR1A1 and 7A2 were much lower than AKR1B and 1C isoform expression. A549 cells were also found to have significantly greater AKR1B10 transcript levels than found in HBEC-KT cells which are more similar to normal lung epithelial cells. As human lung adenocarcinoma cells, A549 cells may not accurately reflect enzyme levels of normal human lung, further studies are required to investigate expression of the AKRs in cell models that better represent normal human lung cells.

Animal models such as rats and mice are often used to study PAH carcinogenesis raising the possibility that more could be learned by the use of AKR knockout or AKR transgenic mice. However, caution should be exercised when rodent models are used to draw conclusions as to the role of human AKRs in PAH carcinogenesis. The most important enzymes to study would be the murine AKR1C enzymes. However, it has been shown that there are no functional orthologs of the AKR1C enzymes in mice (Velica et al., 2009). Among the studies that have been successful, it was found that AKR1B3 (murine aldose reductase) knockout mice exhibited reduced metabolism of advanced glycation end products (AGEs) resulting in AGEs accumulation and atherosclerotic lesion formation (Baba et al., 2009); in addition AKR1B3 knockout mice prevented azoxymethane-induced formation of colonic preneoplastic aberrant crypt foci by a mechanism that may involve reduction of glutathionyl-4-hydroxynonenal to glutathionyl-1,4-dihydroxynonenone (Tammali et al., 2009). In another study, AKR1C18 knockout mice which have 20k-hydroxysteroid dehydrogenase were found to have a parturition defect due to the inability to metabolize progesterone (Pickorz et al., 2005).

CONCLUSION

Aldo-keto reductases catalyze the metabolic activation of structural diverse PAH trans-dihydrodiol proximate carcinogens to yield redox-active and electrophilic PAH o-quinones. AKRs also catalyze the two electron reduction of PAH o-quinones back to the corresponding cognate PAH catechols, establishing a futile redox cycle which results in ROS formation and subsequent oxidative DNA damage in human lung cells. However, the PAH catechols can be intercepted by COMT, SULTs, and UGTs to form conjugated PAH metabolites, which will terminate the redox-cycling. The toxicological outcome of the o-quinone pathway of PAH activation will depend on the balance of the activities of the AKR isoforms and the battery of phase II enzymes implicated in the conjugation process. This balance will be affected by gene expression and polymorphic variants of the enzymes identified.

ACKNOWLEDGMENTS

This work was supported by 1R01-CA39504, P30-ES013508, and Pennsylvania Department of Health non-formula grant SAP Number: 4100038714 awarded to Trevor M. Penning.
Burczynski, M. E., Harvey, R. G., and Penning, T. M. (1998). Expression and characterization of four recombinant human dihydrodiol dehydrogenase isozymes: oxidation of trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated e-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry 37, 6781–6790.

Burczynski, M. E., Lin, H. K., and Penning, T. M. (1999). Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 59, 607–614.

Cappiello, M., Franchi, M., Giuliani, L., Carlini, E. J., Raftogianis, R. B., Wood, A. H. (1982). Induction of oxidation of recombinant human dihydrodiol dehydrogenase by polycyclic aromatic hydrocarbons: activation of wild-type and variant COMT isoforms. Cancer Res. 42, 10937–10942.

Catalle, P., Roodi, N., Mermugh, R. A., Wang, X., and Parf, F. E. (2001). Catalytic-O-methyltransferase (COMT)-mediated metabolism of catalchol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res. 61, 6716–6722.

Chen, W. C., Doherty, R. W., Bohnke, H., and Gross, M. H. (1996). Relationship of human liver dihydrodiol dehydrogenases to human aldol-keto reductase: soluble and particulate forms of rat liver dihydrodiol dehydrogenase. Chem. Res. Toxicol. 9, 1776–1785.

Dawling, S., Raoji, G. S., Mermugh, R. A., Wang, X., and Parf, F. E. (2001). Catalchol-O-methyltransferase (COMT)-mediated metabolism of catalchol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res. 61, 6716–6722.

Eaton, T. M., Ketelhut, D., and Teaphly, T. R. (2000). UDP-glucuronosyltransferases. In J. Assoc. Off. Anal. Chem. 83, 143–161.

Grimmer, G., and Bohnek, H. (1975). Polycyclic aromatic hydrocarbon profile analysis of high-protein foods, oils, and fats by gas chromatography. J. Assoc. Off. Anal. Chem. 38, 725–733.

Habermacher, J., and Breakefield, X. O. (1985). Polycyclic aromatic hydrocarbons as carcinogenic tumor initiators. Cancer Res. 45, 1177–1186.

Huang, M., Blair, I. A., and Penning, T. M. (2007). Metabolism and characterization of four recombinant human dihydrodiol dehydrogenase isozymes for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 59, 607–614.

Jarabak, J. (1991). Polycyclic aromatic hydrocarbon quinones may be either substrates for or irreversible inhibitors of the human placental NAD-linked 15-hydroxyprostaglandin dehydrogenase. Arch. Biochem. Biophys. 292, 239–243.

Jarabak, J. (1992). Characterization of membrane-bound and soluble catalchol-O-methyltransferase from human frontal cortex. J. Neurochem. 62, 822–825.

Jeffrey, D. R., and Roth, J. A. (1998). Characterization of membrane-bound and soluble catalchol-O-methyltransferase from human frontal cortex. J. Neurochem. 62, 822–825.

Jin, Y., and Penning, T. M. (2007). Aldo-keto reductases and bioactivation/detoxification. Annu. Rev. Pharmacol. Toxicol. 47, 263–292.

Kasai, H., Kastin, P., Ruchin, X., Nishizuma, S., Ootaayama, A., and Tannoaka, H. (1986). Formation of 8-hydroxyguanine moiety in cellular DNA by agents producing oxygen radicals and evidence for its repair. Carcinogenesis 7, 1849–1851.

Kerlan, V., Drezno, Y., Bereković, I. P., Beaune, P. H., Floch, H. H., and Berthou, F. (1992). Nature of cytochromes P450 involved in the 2/4-hydroxylations of estradiol in human liver microsomes. Biochem. Pharmacol. 44, 1745–1756.

King, C. D., Rios, G. R., Green, M. D., and Tephly, T. R. (2000). UDP-glucuronosyltransferases. Curr. Drug Metab. 1, 145–161.

Lee, A. Y., Chung, S. K., and Chung, S. S. (1995). Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc. Natl. Acad. Sci. U.S.A. 92, 2780–2784.

Lemonde, H. A., Cantard, E. J., Bouquet, J., Duran, M., Overmars, H., Scambler, P. J., et al. (2003). Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5β-reductase, cause hepatic liver failure in infancy. Gut 52, 1494–1499.

Lietz, J. G., Ulubelen, A. A., and Strobel, H. W. (1986). Cytochrome P450-mediated redox cycling of estrogens. J. Biol. Chem. 261, 16865–16870.
Mannisto, P. T., and Kaakkola, S. (1999). www.frontiersin.org

November 2012 | Volume 3 | Article 193 | 11

Mangal, D., Vudathala, D., Park, J. H., Lee, S. H., Penning, T. M., and Blair, I. A. (2009). Analysis of 7,8-dihydro-8-oxo-2′-deoxyguanosine in cellular DNA during oxidative stress. Chem. Res. Toxicol. 22, 788–797.

Mannisto, P. T., and Kaakkola, S. (1999). Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 51, 593–628.

Martucci, C. P., and Fishman, J. (1993). P450 enzymes of estrogen metabolism. Pharmacol. Ther. 57, 257–257.

McCoud, K. D., Rindgen, D., Blair, I. A., and Penning, T. M. (1999). Synthesis and characterization of polycyclic aromatic hydrocarbon o-quinone depurinating N7-guanine adducts. Chem. Res. Toxicol. 12, 237–246.

Misaki, K., Matsui, S., and Matsuda, T. (2007). Metabolic enzyme induction by HepG2 cells exposed to oxygenated and nonoxygenated polycyclic aromatic hydrocarbons. Chem. Res. Toxicol. 20, 277–283.

Monks, T. J., and Lau, S. S. (1997). Biological reactivity of polynuclear glutathione conjugates. Chem. Res. Toxicol. 10, 1296–1313.

Murry, V. S., and Penning, T. M. (1992a). Characterization of mercapturic acid and glutathionyl conjugates of benzo[a]pyrene-7,8-diene by two-dimensional NMR. Bioconjug. Chem. 3, 218–224.

Murry, V. S., and Penning, T. M. (1992b). Polycyclic aromatic hydrocarbon (PAH) ortho-quinone conjugate chemistry: kinetics of thiol addition to PAH ortho-quinones and structures of thioether adducts of naphthalene-1,2-dione. Chem. Biol. Interact. 84, 169–188.

Nagarajan, W., Walthall, T., Palmichard, R., and L. (2006). Sulfotransferase (SULT) IA1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation. Mol. Pharmacol. 69, 2084–2092.

Negishi, M., Pedersen, L. G., Petrothchenko, E., Shetovtsov, S., Gorokhov, A., Kakuta, Y., et al. (2001). Structure and function of sulfotransferases. Arch. Biochem. Biophys. 390, 149–157.

Olson, K. C., Sun, D., Chen, G., Sharma, A. K., Amin, S., Ropson, I. J., et al. (2011). Characterization of dibenzo[a,j]pyrene-trans-11,12-diol (dibenzo[de,fg]pyrene) glucuronidation by UDP-glucuronosyltransferases. Chem. Res. Toxicol. 24, 1549–1559.

Penning, T. M. (2002). Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells. J. Biol. Chem. 277, 24799–24808.

Penning, T. M. (2004). Aldo-keto reductase enzymes: effect of redox states and regulation on MCF-7 human breast cancer cells. J. Biol. Chem. 281, 2207–2215.

Piekorz, R. P., Gingras, S., Hoffman, A., Bile, J. N., and Weinstein, Y. (2005). Regulation of progestrone levels during pregnancy and parturition by signal transducer and activator of transcription 5 and 20-dehydroxysteroid dehydrogenase. Mol. Endocrinol. 19, 431–440.

Quinn, A. M., Harvey, R. G., and Penning, T. M. (2008). Oxidation of PAH trans-dihydrodiols by human aldo-keto reductase AKR1B10. Chem. Res. Toxicol. 21, 2207–2215.

Raftogianis, R. B., Wood, T. C., and Weinshilboum, R. M. (1999). Human phenol sulfotransferases SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations. Biochem. Pharmacol. 58, 605–616.

Schneider, J., Huh, M. M., Bradlow, H. L., and Fishman, J. (1984). Antiestrogen action of 2-hydroxyestrone and 2-hydroxyestradiol in human breast cancer cells. J. Biol. Chem. 259, 4840–4845.

Shen, Y. M., Troxl, A. B., Vedanta, S., Penning, T. M., and Field, J. (2006). Comparison of p53 mutations induced by PAH o-quinones with those caused by anti-benzo[a]pyrene diol epoxide in vitro: role of reactive oxygen and biological selection. Chem. Res. Toxicol. 19, 1441–1450.

Shou, M., Harvey, R. G., and Penning, T. M. (1993). Reactivity of benzo[a]pyrene-7,8-diene with DNA. Evidence for the formation of deoxyguanosine adducts. Carcinogenesis 14, 475–482.

Suzen, S., and Buyukkengal, E. (2003). Recent studies of aldose reductase enzyme inhibition for diabetic complications. Curr. Med. Chem. 10, 1329–1352.

Syanen, A. C., Tilgmann, C., Rinne, J., and Ullman, I. (1997). Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics 7, 65–71.

Tammali, R., Reddy, A. B., Ramana, K. V., Petrosh, J. M., and Srivasta, S. K. (2009). Aldose reductase deficiency in mice prevents
